Display options
Cite
Huang Y, Wang P, Morales R, et al. Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System. Front Aging Neurosci. 2021;13:651638doi: 10.3389/fnagi.2021.651638.
Huang, Y., Wang, P., Morales, R., Luo, Q., & Ma, J. (2021). Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System. Frontiers in aging neuroscience, 13651638. https://doi.org/10.3389/fnagi.2021.651638
Huang, Yumeng, et al. "Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System." Frontiers in aging neuroscience vol. 13 (2021): 651638. doi: https://doi.org/10.3389/fnagi.2021.651638
Huang Y, Wang P, Morales R, Luo Q, Ma J. Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System. Front Aging Neurosci. 2021 Jun 08;13:651638. doi: 10.3389/fnagi.2021.651638. eCollection 2021. PMID: 34168549; PMCID: PMC8217467.
Copy Download .nbib Format: NLM
Share it on

Front Aging Neurosci. 2021 Jun 08;13:651638. doi: 10.3389/fnagi.2021.651638. eCollection 2021.

Map2k5-Deficient Mice Manifest Phenotypes and Pathological Changes of Dopamine Deficiency in the Central Nervous System.

Frontiers in aging neuroscience

Yumeng Huang, Pei Wang, Rodrigo Morales, Qi Luo, Jianfang Ma

Affiliations

  1. Department of Neurology, Institute of Neurology, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital, Shanghai, China.
  2. Department of Neurology, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, United States.
  3. Centro Integrativo de Biologia y Quimica Aplicada (CIBQA), Universidad Bernardo O'Higgins, Santiago, Chile.

PMID: 34168549 PMCID: PMC8217467 DOI: 10.3389/fnagi.2021.651638

Abstract

MAP2K5, a member of the MAPK family, is associated with central nervous system disorders. However, neural functional of Map2k5 from animal models were not well examined so far. Here, we established a Map2k5-targeted knockout mouse model to investigate the behavior phenotypes and its underlying molecular mechanism. Our results showed that female Map2k5 mutant mice manifested decreased circadian-dependent ambulatory locomotion, coordination, and fatigue. Male Map2k5 mutant mice displayed impairment in open field exploration and prepulse inhibition of acoustic startle response (ASR) when compared with wild-type controls. Furthermore, Map2k5 mutant mice showed a decreased dopaminergic cell survival and tyrosine hydroxylase levels in nigrostriatal pathway, indicating a crucial role of MAP2K5 in regulating dopamine system in the central nervous system. In conclusion, this is the first study demonstrating that Map2k5 mutant mice displayed phenotypes by disturbing the dopamine system in the central nervous system, implicating Map2k5 mutant mouse as a promising model for many dopamine related disorders.

Copyright © 2021 Huang, Wang, Morales, Luo and Ma.

Keywords: MAP2K5; Parkinson’s disease; dopamine; mouse model; restless legs syndrome; sensorimotor phenotypes

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  1. J Neurosci. 2012 Mar 21;32(12):4118-32 - PubMed
  2. J Psychiatr Res. 2020 Apr;123:62-71 - PubMed
  3. Sleep Med. 2014 Aug;15(8):860-73 - PubMed
  4. Psychiatry Investig. 2018 Jan;15(1):84-89 - PubMed
  5. Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9697-702 - PubMed
  6. Genome Res. 2017 Sep;27(9):1487-1500 - PubMed
  7. Int J Dev Neurosci. 2015 Nov;46:44-50 - PubMed
  8. Cell Death Dis. 2015 Apr 09;6:e1718 - PubMed
  9. Neuropsychopharmacology. 2019 Oct;44(11):1975-1984 - PubMed
  10. Neurosci Biobehav Rev. 2002 Jan;26(1):1-11 - PubMed
  11. Parkinsonism Relat Disord. 2015 Jun;21(6):582-5 - PubMed
  12. J Neurosci. 2016 May 18;36(20):5608-22 - PubMed
  13. Brain. 2015 Oct;138(Pt 10):2948-63 - PubMed
  14. J Neurosci Res. 2006 Nov 1;84(6):1367-75 - PubMed
  15. J Biol Chem. 1998 Feb 13;273(7):3854-60 - PubMed
  16. Oncol Rep. 2017 Jan;37(1):83-90 - PubMed
  17. PLoS One. 2013 Apr 22;8(4):e61948 - PubMed
  18. EMBO Rep. 2001 Sep;2(9):829-34 - PubMed
  19. Prog Neuropsychopharmacol Biol Psychiatry. 2018 Feb 2;81:493-500 - PubMed
  20. Antioxid Redox Signal. 2017 Nov 10;27(14):1048-1066 - PubMed
  21. Biol Psychiatry. 2019 Feb 1;85(3):189-201 - PubMed
  22. Mol Neurodegener. 2018 Jan 8;13(1):1 - PubMed
  23. Science. 2002 Dec 6;298(5600):1911-2 - PubMed
  24. Anal Bioanal Chem. 2021 Jan;413(2):377-387 - PubMed
  25. J Affect Disord. 2016 May 15;196:87-96 - PubMed
  26. Sleep Med. 2011 Sep;12(8):800-4 - PubMed
  27. Nat Genet. 2007 Aug;39(8):1000-6 - PubMed
  28. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):1945-9 - PubMed
  29. Nucleic Acids Res. 2018 Jul 2;46(W1):W242-W245 - PubMed
  30. Sleep. 2014 Sep 01;37(9):1535-42 - PubMed
  31. Sleep. 2017 Apr 1;40(4): - PubMed
  32. Ann Pharmacother. 2007 Feb;41(2):285-95 - PubMed
  33. Circ Res. 2019 Apr 12;124(8):1240-1252 - PubMed
  34. Neurology. 2019 May 14;92(20):948-964 - PubMed
  35. J Biol Chem. 2000 Jun 16;275(24):18534-40 - PubMed
  36. Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8532-7 - PubMed
  37. J Trace Elem Med Biol. 2020 May 11;61:126546 - PubMed
  38. Schizophr Res. 2018 Aug;198:68-83 - PubMed
  39. Front Neurosci. 2019 Oct 30;13:1163 - PubMed
  40. Cell Signal. 2016 Mar;28(3):177-189 - PubMed
  41. Rev Neurosci. 2017 Jul 26;28(6):617-648 - PubMed
  42. Mol Cell Biol. 2005 Jan;25(1):336-45 - PubMed
  43. Circ Res. 2017 Jan 6;120(1):66-77 - PubMed
  44. Nat Neurosci. 2019 Dec;22(12):1975-1985 - PubMed

Publication Types